secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lucid Diagnostics Inc. (LUCD)
CIK:        0001799011
Form:       8-K
Filed at:   2023-03-14T23:59:59+00:00
Accession:  0001493152-23-007624
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 2.02, 2.03, 3.02, 3.03, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lucid Diagnostics raises $24.6M in preferred & debt; 4Q22 revenue $0.1M, net loss $14.9M
--------------------------------------------------------------------------------

- Secured $13.6M from Series A preferred stock and $11.1M senior secured convertible note, extending cash runway into 2024.
- 4Q22 EsoGuard test volume 1,174, up 8% sequentially and 288% YoY; projects ~1,600 tests in 1Q23.
- Signed in-network agreement with MultiPlan, expanding access to ~60 million consumers.
- GAAP net loss $14.9M ($0.47/share) in 4Q22; non-GAAP adjusted loss $10.6M ($0.33/share).
- Cash and equivalents $22.5M at Dec 31, 2022, bolstered by subsequent financings.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1799011/000149315223007624/0001493152-23-007624-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1799011/000149315223007624/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-007624

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer